G0FB Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.40 |
52 Week High | €10.60 |
52 Week Low | €4.78 |
Beta | 0.70 |
11 Month Change | -17.95% |
3 Month Change | -22.42% |
1 Year Change | -30.81% |
33 Year Change | -30.75% |
5 Year Change | -68.93% |
Change since IPO | -38.09% |
Recent News & Updates
Recent updates
Shareholder Returns
G0FB | DE Biotechs | DE Market | |
---|---|---|---|
7D | -20.0% | 1.4% | 3.6% |
1Y | -30.8% | -16.5% | 9.0% |
Return vs Industry: G0FB underperformed the German Biotechs industry which returned -16.5% over the past year.
Return vs Market: G0FB underperformed the German Market which returned 8.6% over the past year.
Price Volatility
G0FB volatility | |
---|---|
G0FB Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 6.7% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.7% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G0FB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G0FB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
G0FB fundamental statistics | |
---|---|
Market cap | €5.40b |
Earnings (TTM) | €161.49m |
Revenue (TTM) | €7.01b |
36.3x
P/E Ratio0.8x
P/S RatioIs G0FB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
G0FB income statement (TTM) | |
---|---|
Revenue | €7.01b |
Cost of Revenue | €4.26b |
Gross Profit | €2.75b |
Other Expenses | €2.58b |
Earnings | €161.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.24 |
Gross Margin | 39.18% |
Net Profit Margin | 2.31% |
Debt/Equity Ratio | 123.2% |
How did G0FB perform over the long term?
See historical performance and comparison